Long-Term Follow-up Protocol for Participants Treated With Gene-Modified T Cells
Key facts
- Where
- Berlin, Chemnitz, Cologne, Dresden, Duesseldorf, Erlangen, Essen, Frankfurt Am Main, Hamburg, Hanover, Heidelberg, Karlsruhe, Magdeburg, Munich, Regensburg, Tuebingen, Ulm, and Wuerzburg, GermanySee the 21 sites
- Phase
- Phase 2/3
Where in Germany
- Charite Universitaetsmedizin Berlin KöRBerlin, GermanyTaking people
- HELIOS Klinikum Berlin Buch GmbHBerlin, GermanyTaking people
- Klinikum Chemnitz gGmbHChemnitz, GermanyTaking people
- Universitaetsklinikum Koeln AöRCologne, GermanyTaking people
- University Hospital Cologne AöRCologne, GermanyTaking people
- Universitaetsklinikum Carl Gustav Carus Dresden an der Technischen Universitaet Dresden AöRDresden, GermanyTaking people
- Universitaetsklinikum Duesseldorf AöRDuesseldorf, GermanyTaking people
- Universitaetsklinikum Erlangen AöRErlangen, GermanyTaking people
- Universitaetsklinikum Essen (AoR)Essen, GermanyTaking people
- Universitaetsklinikum Frankfurt AöRFrankfurt Am Main, GermanyTaking people
- University Medical Center Hamburg-EppendorfHamburg, GermanyTaking people
- Medizinische Hochschule HannoverHanover, GermanyTaking people
- Universitaetsklinikum Heidelberg AöRHeidelberg, GermanyTaking people
- Staedtisches Klinikum Karlsruhe gGmbHKarlsruhe, GermanyTaking people
- Otto Von Guericke Universitaet MagdeburgMagdeburg, GermanyTaking people
- Klinikum der Technischen Universitaet Muenchen (TUM Klinikum)Munich, GermanyTaking people
- Klinikum der Universitaet Muenchen AöRMunich, GermanyTaking people
- Universitaetsklinikum Regensburg AöRRegensburg, GermanyTaking people
- Universitaetsklinikum Tuebingen AöRTuebingen, GermanyTaking people
- Universitaetsklinikum Ulm AoRUlm, GermanyTaking people
- Universitaetsklinikum Wuerzburg AöRWuerzburg, GermanyTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Celgene
- Trial code
- NCT03435796EU 2023-504201-36-00
- Record updated
- 2 November 2026
- Original description
This is a prospective study for the long-term follow-up (LTFU) of safety and efficacy for all pediatric and adult participants exposed to Gene-modified (GM) T-cell therapy participating in a previous Celgene sponsored or Celgene alliance partner sponsored study.Read full original descriptionShow less
Long-Term Follow-up Protocol for Subjects Treated With Gene-Modified T Cells
This is a prospective study for the long-term follow-up (LTFU) of safety and efficacy for all pediatric and adult participants exposed to Gene-modified (GM) T-cell therapy participating in a previous Celgene sponsored or Celgene alliance partner sponsored study.
Participants who received at least one infusion of GM T cells will be asked to enroll in this LTFU protocol upon either premature discontinuation from, or completion of the prior parent treatment protocol.
Inclusion: Received at least one gene-modified (GM) T-cell infusion in a previous Celgene sponsored, Juno Therapeutics, other affiliates of BMS, or Celgene alliance partner-sponsored trial, and have discontinued, or completed the post-treatment follow-up period in the parent treatment protocol, as applicable; Must understand and voluntarily sign an Informed Consent Form/Informed Assent Form prior to any study-related assessments/procedures being conducted.
Exclusion: Not Applicable; Other protocol-defined inclusion/exclusion criteria apply.